MICHEL VAYSSAIRAT, M.D.; LOIC CAPRON, M.D.; JEAN-NÖEL FIESSINGER, M.D.; JEAN-FRANÇOIS MATHIEU, M.D.; EDWARD HOUSSET, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: The letter by Kahan and associates (1), prompts us to report the main findings of a study on the effects of another calcium channel blocking agent, Diltiazem, in Raynaud's disease. A detailed description of these results is in preparation.
Twenty six patients with Raynaud's disease (19 men; seven women; mean age, 36 years; mean follow-up of disease, 7 years; reasonably excluding all cases of secondary Raynaud's phenomenon) were observed for two consecutive periods of 14 days. During the first period no treatment was given (baseline observation). During the second period, patients were randomly allocated to either placebo
VAYSSAIRAT M, CAPRON L, FIESSINGER J, et al. Calcium Channel Blockers and Raynaud's Disease. Ann Intern Med. 1981;95:243. doi: 10.7326/0003-4819-95-2-243_2
Download citation file:
Published: Ann Intern Med. 1981;95(2):243.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use